Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company also develops Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other GI diseases, as well as nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-254-5555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
OptionableOptionable
Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions
What is Albireo Pharma's stock symbol?
Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."
How were Albireo Pharma's earnings last quarter?
Albireo Pharma Inc (NASDAQ:ALBO) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.98) by $0.24. The biopharmaceutical company earned $0.73 million during the quarter, compared to analyst estimates of $2 million. View Albireo Pharma's Earnings History.
When is Albireo Pharma's next earnings date?
What price target have analysts set for ALBO?
4 analysts have issued 12 month target prices for Albireo Pharma's stock. Their predictions range from $50.00 to $69.00. On average, they expect Albireo Pharma's stock price to reach $56.3333 in the next twelve months. This suggests a possible upside of 113.5% from the stock's current price. View Analyst Price Targets for Albireo Pharma.
What is the consensus analysts' recommendation for Albireo Pharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.
What are Wall Street analysts saying about Albireo Pharma stock?
Here are some recent quotes from research analysts about Albireo Pharma stock:
- 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (11/15/2018)
- 2. Needham & Company LLC analysts commented, "Albireo provided a quarterly corporate update today and hosted an analyst/ investor event at the AASLD mtg yesterday. Mgmt reported progress w/ Phase 3 PEDFIC1 trial of IBAT inhibitor A4250 in PFIC1/2, announcing that 26 sites have now been opened. Top-line results are still expected around YE19. Recent presentations at NASPGHAN and AASLD mtgs provide additional context around PFIC natural history, unmet need, and A4250 therapeutic strategy. Mgmt continues to guide for another A4250 trial initiation in 2019, most likely Biliary Atresia or Alagille Syndrome. Reiterate BUY. Stock does not adequately reflect value of development efforts in pediatric liver disease." (11/13/2018)
Has Albireo Pharma been receiving favorable news coverage?
Media stories about ALBO stock have trended neutral on Saturday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Albireo Pharma earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the next few days.
Who are some of Albireo Pharma's key competitors?
Some companies that are related to Albireo Pharma include Esperion Therapeutics (ESPR), Phibro Animal Health (PAHC), Amphastar Pharmaceuticals (AMPH), Vanda Pharmaceuticals (VNDA), Wave Life Sciences (WVE), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), Tricida (TCDA), Advanz Pharma (CXRXF), MacroGenics (MGNX) and Retrophin (RTRX).
Who are Albireo Pharma's key executives?
Albireo Pharma's management team includes the folowing people:
- Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 56)
- Ms. Martha J. Carter, Chief Regulatory Officer (Age 67)
- Dr. Paresh N. Soni, Consultant (Age 59)
- Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
- Mr. Simon Harford, CFO & Treasurer
Who are Albireo Pharma's major shareholders?
Albireo Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.89%), Prosight Management LP (2.26%), Sectoral Asset Management Inc (1.92%), Fosun International Ltd (1.65%), Dimensional Fund Advisors LP (0.97%) and Geode Capital Management LLC (0.81%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Life Sciences Maste Perceptive, Phase4 Partners Ltd, Plc Astrazeneca and Ronald Harold Wilfred Cooper. View Institutional Ownership Trends for Albireo Pharma.
Which institutional investors are selling Albireo Pharma stock?
Which institutional investors are buying Albireo Pharma stock?
ALBO stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Prosight Management LP, Sectoral Asset Management Inc, Dimensional Fund Advisors LP, Victory Capital Management Inc., Geode Capital Management LLC, Alps Advisors Inc. and Weiss Multi Strategy Advisers LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.
How do I buy shares of Albireo Pharma?
Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albireo Pharma's stock price today?
One share of ALBO stock can currently be purchased for approximately $26.38.
How big of a company is Albireo Pharma?
Albireo Pharma has a market capitalization of $315.77 million. The biopharmaceutical company earns $-24,410,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Albireo Pharma employs 22 workers across the globe.
What is Albireo Pharma's official website?
How can I contact Albireo Pharma?
Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]
MarketBeat Community Rating for Albireo Pharma (NASDAQ ALBO)
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
